A PC-9 PC-9/AR B PC-9/GR PC-9/GR/AR AZD9291 AZD9291 AZD9291 AZD9291

Slides:

Advertisements

Similar presentations

Supplementary Figure S1

Advertisements

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Slide 1Fig 28-CO, p.858. Slide 2Fig 28-1, p.859 Slide 3Fig Q28-19, p.884.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure S1 Inhibition of AKT and S6 phosphorylation. After 4 h treatment with 1 µM of GDC-0941, EVSA-T parental, resistant Clone1, Clone2,

Farmer et al Supplementary Figure 1 KU PARP-1 IC 50 = 3.2nM KU PARP-1 IC 50 = 3.4nM KU PARP-1 IC 50 = 730nM a b

ΜΕΤΑΣΥΛΛΕΚΤΙΚΗ ΦΥΣΙΟΛΟΓΙΑ ΕΡΓΑΣΤΗΡΙΟ 3. Μετασυλλεκτική Εργ3-Λιοσάτου Γ.2 ΒΙΟΛΟΓΙΚΟΙ ΠΑΡΑΓΟΝΤΕΣ ΠΟΥ ΕΠΗΡΕΑΖΟΥΝ ΤΗ ΦΘΟΡΑ ΤΩΝ ΟΠΩΡΟΚΗΠΕΥΤΙΚΩΝ Αναπνοή Η λειτουργία.

Fig. 6-CO, p p. 185a p. 185b p. 185c p. 185d.

Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

A. B. BxPC-3 PANC h h h h h 100 *** * 72 h Cell viability (%) 80 *** *** Cell viability (%) 80 *** *** 60 *** ***

Drug concentration (μM)

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.

Schematic of the Cell Cycle of Eukaryotic Cells

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Strong radioprotective FGF1 signaling down-regulates proliferative and metastatic capabilities of the angiosarcoma cell line, ISOS-1, through the dual.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.

Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

اثرات گرمايش جهاني تغييرات آب و هوا، تأثيرات عميق و شديدي بر بسياري از عوامل اساسي موثر بر سلامت از جمله : آب، غذا، هوا و محيط زيست دارد كه اين مورد خود.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

β-ARs signal cooperatively with mutant EGFR and inactivate LKB1

Fig. 4. Functional annotation of VUS in EGFR.

Beyond Erlotinib: Better EGFR Inhibitors?

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation Silvia La Monica,

LNCaP * C4-2B Du145 22Rv1 SI Figure 1. miR-124 inhibits the proliferation of CaP cells. WST-1 cell proliferation analysis of AR-positive CaP cell lines.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib Helena A. Yu,

TBP 200 LC2/ad MGH134 MGH134 CCDC6-RET MGH134 EV CCDC6-RET PC9

Detection rate for EGFR mutations in cfDNA.

Fig. 5. GUCD1 was a direct target of miR-370 in HCC

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer Edward.

Fig. 6-CO, p. 211.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells Duc-Hiep Bach,

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation Junya Nakade,

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

XIST regulated miR-29c by directly targetting in TMZ-resistant glioma cells XIST regulated miR-29c by directly targetting in TMZ-resistant glioma cells.

Effects of XIST on glioma cell proliferation and chemoresistance to TMZ Effects of XIST on glioma cell proliferation and chemoresistance to TMZ (A) siRNA-NC/siRNA-XIST.

Fig. 3. TKI sensitivity assessed by the MANO method.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding.

Growth inhibition rate with patritumab

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy Alvaro Quintanal-Villalonga, PhD, Sonia.

The oligoclonal antibody overcomes the C797S mutation‐mediated resistance to osimertinib The oligoclonal antibody overcomes the C797S mutation‐mediated.

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

A B C D E control CORM-2 (10mM) iCORM (10mM) L-NAME (500mM)

Chronic PDGFRα activation reduces sensitivity of PDGFRα-positive GBM cells to translational inhibitor–induced suppression on cell viability. Chronic PDGFRα.

Volume 17, Issue 1, Pages (January 2010)

CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.

Active AR signaling in enzalutamide-resistant xenograft tumors.

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.

Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma cells. Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma.

ERK reactivation following EGFR TKI treatment.

Location of common clinically relevant mutations in EGFR

CDs with KRASG12C cooperatively sustain downstream signaling outputs to promote survival and proliferation. CDs with KRASG12C cooperatively sustain downstream.

THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.

Afatinib rapidly destabilizes endogenous TRIB2 and specifically induces caspase 3 cleavage and U937 cytotoxicity. Afatinib rapidly destabilizes endogenous.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

TRK inhibitor binding to acquired resistance mutations.

Presentation transcript:

A PC-9 PC-9/AR B PC-9/GR PC-9/GR/AR AZD9291 AZD9291 AZD9291 AZD9291 CO1686 CO1686 CO1686 CO1686 Erlotinib Erlotinib Erlotinib Erlotinib 25 50 75 100 1 10 1000 10000 Cell number (% of control) Conc. [nM] 25 50 75 100 1 10 1000 10000 Cell number (% of control) Conc. [nM] C Fig. S1. Establishment of AZD9291-resistant cell lines from PC-9 or PC9-GR cells (A and B) and detection of EGFR T797S mutation (C). A and B, The given cell lines were exposed to different concentrations of tested EGFR-TKIs as indicated for 3 days. Cell numbers were estimated with the SRB assay. The data are means ± SDs of four replicate determinations. C, EGFR mutations were detected using ICE COLD-PCR.